AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Alkermes (ALKS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

35.93

0.04 (0.11%)

At close: Feb 18, 2025, 3:59 PM

35.90

-0.08%

After-hours: Feb 18, 2025, 05:04 PM EST

undefined% (undefined)

Bid	33.95
Market Cap	5.84B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.2
PE Ratio (ttm)	16.33
Forward PE	n/a
Analyst	Buy

Ask	37.62
Volume	1,437,429
Avg. Volume (20D)	1,654,335
Open	35.78
Previous Close	35.89
Day's Range	35.41 - 36.45
52-Week Range	22.90 - 36.45
Beta	undefined

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the tre...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 16, 1991

Employees 1,800

Stock Exchange NASDAQ

Ticker Symbol ALKS

Website https://www.alkermes.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 4.37% from the latest price.

Buy 75.00%

Hold 16.67%

Sell 8.33%

Stock Forecasts

Next Earnings Release

Alkermes is scheduled to release its earnings on Apr 30, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

6 months ago

+6.04%

Alkermes shares are trading higher after the compa... Unlock content with Pro Subscription

10 months ago

+3.09%

Alkermes shares are trading higher after the company announced topline results from its Phase 1b study of ALKS 2680 in patients with Narcolepsy Type 2 and Idiopathic Hypersomnia.

News

5 days ago · zacks.com

Alkermes' Q4 Earnings & Revenues Surpass Estimates, Stock Up

ALKS reports better-than-expected fourth-quarter 2024 results. Net sales of proprietary products increase year over year.

1 week ago · seekingalpha.com

Alkermes plc (ALKS) Q4 2024 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS ) Q4 2024 Earnings Conference Call February 12, 2025 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs and Investor Relations Richard...

6 days ago · fool.com

Alkermes Plc EPS Soars Past Forecasts

Alkermes (ALKS 2.50%), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported ro...

6 days ago · zacks.com

Alkermes (ALKS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Str...

6 days ago · zacks.com

Alkermes (ALKS) Q4 Earnings and Revenues Surpass Estimates

Alkermes (ALKS) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.48 per share a year ago.

1 week ago · zacks.com

What Analyst Projections for Key Metrics Reveal About Alkermes (ALKS) Q4 Earnings

Beyond analysts' top -and-bottom-line estimates for Alkermes (ALKS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarte...

2 months ago · seekingalpha.com

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Alkermes has shifted from royalty-based revenues to proprietary product sales, driven by strong growth in Lybalvi, Vivitrol, and Aristada. ALKS 2680, a Phase 2 orexin-2 receptor agonist for narcolepsy...